2025-12-20 - Analysis Report
Okay, here's a breakdown of the provided data for Natera Inc. (NTRA), followed by a comprehensive analysis.

**1. Return Rate Comparison (NTRA vs. S&P 500)**

*   **NTRA Company Overview:** Natera Inc. is a genetic testing company specializing in non-invasive prenatal testing (NIPT) and cancer screening.
*   **NTRA Cumulative Return:** 137.67%
*   **VOO (S&P 500) Cumulative Return:** 101.15%
*   **Divergence:** 36.2 (Relative Divergence: 47.4)

**Analysis:** NTRA has significantly outperformed the S&P 500, with a cumulative return approximately 36.2 percentage points higher.  The relative divergence of 47.4 indicates that the current outperformance is near the middle of its historical range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha    | Beta   | Cap(B) |
|------------|---------|-------|----------|--------|--------|
| 2015-2017  | -10.0%  | 70.1% | -34.0%   | -0.2   | 1.2    |
| 2016-2018  | 22.0%   | 80.0% | 6.0%     | 0.1    | 1.9    |
| 2017-2019  | 50.0%   | 80.0% | 28.0%    | 1.0    | 4.7    |
| 2018-2020  | 186.0%  | 80.5% | 163.0%   | 1.1    | 13.9   |
| 2019-2021  | 96.0%   | 80.5% | 49.0%    | 1.6    | 13.0   |
| 2020-2022  | -77.0%  | 80.5% | -76.0%   | 0.1    | 5.6    |
| 2021-2023  | -194.0% | 76.6% | -195.0%  | -1.1   | 8.7    |
| 2022-2024  | 8.0%    | 76.6% | -13.0%   | -1.2   | 22.1   |
| 2023-2025  | 165.0%  | 76.6% | 99.0%    | 0.1    | 32.4   |

**Analysis:**

*   **CAGR:** Fluctuates significantly, indicating periods of high growth and substantial decline.
*   **MDD (Maximum Drawdown):**  Consistently high, showing significant potential for losses.
*   **Alpha:**  Shows periods of both positive and negative alpha, indicating outperformance and underperformance relative to the market. Note in 2021-2023 alpha is significantly low.
*   **Beta:**  Generally around 1, indicating that NTRA's volatility is similar to the market, but with periods of higher (2019-2021) and lower (2015-2017, 2021-2024) correlation.
*   **Cap:** Market capitalization fluctuates with the ups and downs with the stock.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 231.96
*   **Last Market Data:** Price: 231.96, Previous Close: 224.74, Change: 3.21
*   **5-day SMA:** 227.60
*   **20-day SMA:** 234.50
*   **60-day SMA:** 203.50

**Analysis:** The price is above the 5-day and 60-day moving averages but below the 20-day moving average. This suggests a potential short-term pullback after a recent upward trend, but the longer-term trend remains positive. The recent price increase (change of 3.21) suggests some upward momentum.

**3. RSI, PPO Index, and Other Indicators**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 42.84
*   **PPO:** -1.26
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) Relative Divergence Change:** -2.4 (negative: short-term decline)
*   **Expected Return (%):** -50.6%

**Analysis:**

*   **MRI:** Suggests a medium level of risk, making it a moderately attractive investment based on this indicator alone.
*   **RSI:** At 42.84, the RSI is neutral, indicating neither overbought nor oversold conditions.
*   **PPO:** A negative PPO (-1.26) suggests that short-term moving averages are below longer-term moving averages, indicating a possible downtrend or loss of momentum.
*   **Hybrid Signal:** Despite the MRI is on the medium range, the system strongly recommends purchasing the stock.
*   **Divergence Change:** The negative change in relative divergence suggests a recent short-term decline in NTRA's performance compared to the S&P 500.
*   **Expected Return:** The significantly negative expected return (-50.6%) is a major red flag, suggesting potential underperformance compared to the S&P 500 over the long term.

**4. Recent News & Significant Events**

*   **Positive Headlines:**
    *   Barclays Raises Natera (NTRA) Price Target to $270
    *   Is Natera’s 425.8% Three Year Surge Still Supported by Its Growth Story in 2025?
*   **Neutral/Cautious Headlines:**
    *   Why Natera Remains A 'Hold' For Me Despite Surging MRD Growth And Fatter Margins
*   **Negative Headlines:**
    *   Solomon Moshkevich Sells 4,692 Shares of Natera (NASDAQ:NTRA) Stock
*   **Other News:**
    *   Blood test helps spot colon cancer patients who gain from celecoxib
    *   This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now (Potentially not directly related to NTRA but could influence investor sentiment).

**Analysis:**  The news is mixed. The analyst price target increase is positive, and the article about its growth story is also encouraging. However, insider selling is generally considered a negative signal, and the "Hold" recommendation suggests some caution. The colon cancer test news could be a positive catalyst depending on its impact on revenue.

**4.2 Analyst Opinions:**

*   **Consensus:** Strong Buy (1.47) based on 19 opinions.
*   **Target Price:** Average: $244.42, High: $280.00, Low: $186.00
*   **Recent Rating Changes:** (None provided - data missing)

**Analysis:** Analyst consensus is very positive, with a strong buy rating and a target price that is above the current price. However, it's important to consider the range of target prices, which indicates some disagreement among analysts.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-11-07 | -0.64 | 0.59 B$    |
| 2025-08-08 | -0.74 | 0.55 B$    |
| 2025-05-09 | -0.50 | 0.50 B$    |
| 2024-11-12 | -0.26 | 0.44 B$    |
| 2025-11-07 | -0.26 | 0.44 B$    |

**Analysis:**

*   The company is consistently reporting negative EPS, indicating a lack of profitability.
*   Revenue is increasing over the period, which is a positive sign, but not enough to offset the losses. The first reported values are misaligned.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-09-30 | $0.59B   | 64.91%        |
| 2025-06-30 | $0.55B   | 63.41%        |
| 2025-03-31 | $0.50B   | 63.12%        |
| 2024-12-31 | $0.48B   | 62.94%        |
| 2024-09-30 | $0.44B   | 61.79%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE     |
|------------|----------|---------|
| 2025-09-30 | $1.25B   | -6.99%  |
| 2025-06-30 | $1.25B   | -8.10%  |
| 2025-03-31 | $1.24B   | -5.40%  |
| 2024-12-31 | $1.20B   | -4.50%  |
| 2024-09-30 | $0.88B   | -3.60%  |

**Analysis:**

*   Revenue is consistently growing quarter over quarter, indicating strong sales performance.
*   The profit margin is high and relatively stable, suggesting a strong pricing power.
*   Equity is increasing, a sign of financial health.
*   However, Return on Equity (ROE) is consistently negative, indicating that the company is not generating profits from its equity investments.

**7. Comprehensive Analysis (Summary)**

NTRA presents a mixed picture.

*   **Positives:**
    *   Historically strong outperformance compared to the S&P 500.
    *   Strong revenue growth and high profit margins.
    *   Positive analyst consensus and price targets.
    *   Recent price increase and above-average volume.
*   **Negatives:**
    *   High historical volatility (MDD).
    *   Consistently negative EPS and ROE, indicating a lack of profitability.
    *   Negative expected return (-50.6%) over the long term.
    *   Recent negative change in relative divergence (short-term underperformance).
    *   Insider selling.

**Overall Recommendation:** The analysis suggests a **cautious approach** to investing in NTRA. While the company exhibits strong revenue growth and a high profit margin, the lack of profitability and the negative expected return are significant concerns. The positive analyst ratings and price targets provide some encouragement, but they should be weighed against the company's financial challenges. The mixed news flow further complicates the decision. The final decision depends on your individual risk tolerance and investment horizon.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.